- Bunn HF.
New agents that stimulate erythropoiesis. Blood. 2007 Feb 1;109(3):868-73.
Más información
- de Francisco AL, Sulowicz W, Klinger M, Niemczyk S, Vargemezis V,
Metivier F, Dougherty FC, Oguey D; BA16260 Study Invesigators.
Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals
corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple-dose,
phase II study International Journal of Clinical Practice 2006 Dec;60(12):1687-96.
Más información
- Kerr PG.
Renal anaemia: Recent developments, innovative approaches and future directions for
improved management (Review Article). Nephrology (Carlton). 2006 Dec;11(6):542-8.
Más información
- Macdougall I, Robson R, Opatrna S, Liogier X, Pannier A,
Jordan P, Dougherty F, Reigner B.
Pharmacokinetics and Pharmacodynamics of Intravenous and Subcutaneous Continuous
Erythropoietin Receptor Activator (C.E.R.A.) in Patients with Chronic Kidney Disease.
Clin J Am Soc Nephrol. 2006 Nov;1:1211-1215.
Más información
- Fan Q, Leuther KK, Holmes CP, Fong KL, Zhang J, Velkovska S, Chen MJ, Mortensen
RB, Leu K, Green JM, Schatz PJ, Woodburn KW.
Preclinical evaluation of Hematide, a novel erythropoiesis stimulating agent, for the treatment of anemia.
Exp Hematol. 2006 Oct;34(10):1303-11
Más información
- Sharma B, Ryan MH, Boven K.
Reactions to Eprex"s adverse reactions. Nat Biotechnol. 2006 Oct;24(10):1199-200; author reply 1200.
Más información
- Macdougall IC, Eckardt KU.
"Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia" Lancet. 2006 Sep 9;368(9539):947-53.
Más información
- Stead RB, Lambert J, Wessels D, Iwashita JS, Leuther KK,
Woodburn KW, Schatz PJ, Okamoto DM, Naso R, Duliege AM.
Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1,
double-blind, placebo-controlled, dose-escalation study in healthy volunteers. 2006 Sep 15;108(6):1830-4.
Más información
- Macdougall IC.
Recent advances in erythropoietic agents in renal anemia. Semin Nephrol. 2006 Jul;26(4):313-8.
Más información
- Schellekens H, Jiskoot W.
Eprex-associated pure red cell aplasia and leachates. Nat Biotechnol. 2006 Jun;24(6):613-4. No abstract available.
Más información
- Melnikova I.
Anaemia therapies. Nat Rev Drug Discov. 2006 Aug;5(8):627-8.
Más información
- Bernhardt WM, Campean V, Kany S, Jurgensen JS, Weidemann A, Warnecke C,
Arend M, Klaus S, Gunzler V, Amann K, Willam C, Wiesener MS, Eckardt KU.
Preconditional activation of hypoxia-inducible factors ameliorates ischemic acute renal failure.J Am Soc Nephrol.
2006 Jul;17(7):1970-8. Epub 2006 Jun 8.
Más información
- Macdougall IC.
CERA (Continuous Erythropoietin Receptor Activator): a new erythropoiesis-stimulating agent for the treatment of anemia .
Curr Hematol Rep. 2005 Nov;4(6):436-40. Review.
Más información
- Crommelin D, Bermejo T, Bissig M, Damiaans J, Kramer I, Rambourg P, Scroccaro G,
Strukelj B, Tredree R, Ronco C.
Biosimilars, generic versions of the first generation of therapeutic proteins: do they exist?
Contrib Nephrol. 2005;149:287-94. Review
Más información
- Schellekens H.
Follow-on biologics: challenges of the "next generation". Nephrol Dial Transplant.
2005 May;20 Suppl 4:iv31-36. Review.
Más información
|